{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:24:58Z","timestamp":1761895498038},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>While remission is possible in patients with ankylosing spondylitis (AS), it is often unclear what attitude should be adopted once remission has occurred. We investigated whether dosage adjustment is an effective means of maintaining remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This was a retrospective study drawn from clinical situations. Remission was defined using clinical measures [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \u2264 20\/100 and no peripheral joint disease] and biological measures [C-reactive protein (CRP) levels \u2264 normal value]. The tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors used were infliximab, adalimumab, and etanercept. Response predictors of remission were evaluated by logistic regression (age, CRP, HLA-B27 positivity, sex, duration of disease, and anti-TNF-\u03b1 naivety). CRP and BASDAI were evaluated before and after dosage adjustment at about 6, 12, 24, and 36 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>One hundred eighty-nine patients with AS were included in the study, with a mean followup of 43.5 (\u00b1 17.9) months after the introduction of the first anti-TNF-\u03b1 inhibitor. Mean age was 45.6 (\u00b1 12.5) years. Remission had occurred in 65 patients (35%). Significant response predictors of remission were male sex (p = 0.003) and anti-TNF-\u03b1 naivety (p &lt; 0.001). Dosage adjustment was observed 49 times, and progressively reducing treatment frequency was effective to maintain remission in a large number of patients for 36 months. The cumulative probability of continuing anti-TNF-\u03b1 after dosage adjustment was 79.0% at 12 months, 70.5% at 24 months, and 58.8% at 36 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Remission had occurred in 35% of the patients with AS under anti-TNF-\u03b1 inhibitor therapy. Dosage adjustment and progressively reducing treatment frequency was effective in maintaining remission.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.111337","type":"journal-article","created":{"date-parts":[[2012,6,17]],"date-time":"2012-06-17T21:21:49Z","timestamp":1339968109000},"page":"1418-1423","source":"Crossref","is-referenced-by-count":37,"title":["Dosage Adjustment of Anti-Tumor Necrosis Factor-\u03b1 Inhibitor in Ankylosing Spondylitis Is Effective in Maintaining Remission in Clinical Practice"],"prefix":"10.3899","volume":"39","author":[{"given":"JULIEN","family":"PACCOU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARIE-ASTRID","family":"BACL\u00c9-BOUTRY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ELISABETH","family":"SOLAU-GERVAIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PEGGY","family":"BELE-PHILIPPE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"REN\u00c9-MARC","family":"FLIPO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2012,6,15]]},"reference":[{"key":"2018112909280247000_39.7.1418.1","doi-asserted-by":"publisher","DOI":"10.1186\/ar592"},{"key":"2018112909280247000_39.7.1418.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70039-9"},{"key":"2018112909280247000_39.7.1418.3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020875"},{"key":"2018112909280247000_39.7.1418.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.20852"},{"key":"2018112909280247000_39.7.1418.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"2018112909280247000_39.7.1418.6","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"2018112909280247000_39.7.1418.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2018112909280247000_39.7.1418.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.24557"},{"key":"2018112909280247000_39.7.1418.9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1722-5"},{"key":"2018112909280247000_39.7.1418.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0674-2"},{"key":"2018112909280247000_39.7.1418.11","first-page":"510","article-title":"Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis","volume":"34","author":"Baraliakos","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909280247000_39.7.1418.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2018112909280247000_39.7.1418.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2018112909280247000_39.7.1418.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040758"},{"key":"2018112909280247000_39.7.1418.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.02.005"},{"key":"2018112909280247000_39.7.1418.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh475"},{"key":"2018112909280247000_39.7.1418.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"2018112909280247000_39.7.1418.18","doi-asserted-by":"publisher","DOI":"10.1186\/ar1693"},{"key":"2018112909280247000_39.7.1418.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel015"},{"issue":"Suppl","key":"2018112909280247000_39.7.1418.20","first-page":"S215","article-title":"Can we discontinue anti-TNF therapy in patients with ankylosing spondylitis and remission? A systematic literature review [abstract]","volume":"62","author":"Abad","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2018112909280247000_39.7.1418.21","first-page":"271","article-title":"Flexibilization of infliximab dose interval in the treatment of ankylosing spondylitis","volume":"32","author":"Vinagre","year":"2007","journal-title":"Acta Reumatol Port"},{"key":"2018112909280247000_39.7.1418.22","first-page":"558","article-title":"Prospective observational analysis of the efficacy and safety of low-dose (3 mg\/kg) infliximab in ankylosing spondylitis: 4-year followup","volume":"33","author":"Keeling","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909280247000_39.7.1418.23","first-page":"513","article-title":"Low dose of infliximab is inadequate in most patients with spondylarthropathies","volume":"23","author":"Sidiropulos","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909280247000_39.7.1418.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel156"},{"key":"2018112909280247000_39.7.1418.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.111337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:19:26Z","timestamp":1543515566000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.111337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,7,1]]},"published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.3899\/jrheum.111337"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.111337","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,15]]}}}